An AI-designed “universal vaccine” aimed at protecting against multiple coronaviruses has passed its first human clinical trial phase, according to reports. The vaccine is designed to target more than one coronavirus, with the goal of providing broader immunity than vaccines aimed at a single virus or strain. In the trial, researchers enroll 39 healthy volunteers. Results reported across outlets indicate that the vaccine triggers immune responses in participants, suggesting it is capable of generating protective activity against the targeted coronaviruses. The sources describe this milestone as an early step in developing a vaccine that could help reduce the impact of future coronavirus outbreaks or pandemics by preparing the immune system for multiple related viruses. The reports frame the study as an initial evaluation in humans, and they do not present long-term effectiveness or safety outcomes beyond the early immune response data. Further clinical testing would be required to confirm durability of the immune response, effectiveness against infection, and broader safety in larger and more diverse populations.